-
1 Comment
Novacyt S.A is currently in a long term downtrend where the price is trading 47.1% below its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.2.
Based on the above factors, Novacyt S.A gets an overall score of 1/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | PA |
CurrencyCode | EUR |
ISIN | FR0010397232 |
Market Cap | 34M |
---|---|
PE Ratio | None |
Target Price | 4.12 |
Beta | 0.43 |
Dividend Yield | None |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Le Vésinet, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALNOV.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025